Proof of Concept Study of Eurartesim in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary)
- Indications Vivax malaria
- Focus Proof of concept; Therapeutic Use
- Sponsors Alfasigma; sigma-tau SpA
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2017 Status changed from recruiting to discontinued due to low recruitment.
- 03 May 2017 This trial has been discontinued in Germany (end date: 31 Dec 2016).